Claim being checked · Version 1 · Reviewed
“Afamelanotide increases pain-free light exposure in adults with EPP.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Supported with scope. The reviewed evidence supports this exact statement only in the situation described below.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for Afamelanotide.
01 · Answer
Supported with scope
The label and randomized trials support this defined rare-disease outcome.
- What kind of evidence this is
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- What this answer covers
- Adults with a history of phototoxic reactions from erythropoietic protoporphyria. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Clinical outcomes. What a study measured about people's health, symptoms, or ability to function.
02 · Sources
Read the sources behind this answer
01Afamelanotide for erythropoietic protoporphyriaPubMed · New England Journal of Medicine · Randomized trial · 2015
Supports the scoped claim02SCENESSE (afamelanotide) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the scoped claim
Supports the scoped claim02SCENESSE (afamelanotide) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.